Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Treasury Shares (2018 - 2025)

Aytu Biopharma (AYTU) has disclosed Treasury Shares for 8 consecutive years, with $4.0 as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares fell 99.29% to $4.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0, a 99.29% decrease, with the full-year FY2024 number at $1775.0, down 95.34% from a year prior.
  • Treasury Shares was $4.0 for Q4 2025 at Aytu Biopharma, roughly flat from $4.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.1 million in Q1 2022 to a low of $4.0 in Q3 2025.
  • A 5-year average of $208689.9 and a median of $33424.0 in 2021 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: tumbled 99.95% in 2021, then surged 119579.79% in 2022.
  • Aytu Biopharma's Treasury Shares stood at $33424.0 in 2021, then increased by 29.48% to $43276.0 in 2022, then tumbled by 93.3% to $2898.0 in 2023, then tumbled by 80.5% to $565.0 in 2024, then plummeted by 99.29% to $4.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Treasury Shares are $4.0 (Q4 2025), $4.0 (Q3 2025), and $34528.0 (Q1 2025).